托法替布对类风湿关节炎患者的干预效果分析

Analysis of Intervention Effect of Tofacatib on Patients with Rheumatoid Arthritis

目的:探讨与分析托法替布对类风湿关节炎患者的干预效果.方法:选择2021年6月—2023年1月我院收治的80例类风湿关节炎患者作为研究对象,根据随机数字表法分为托法替布组与对照组,各40例.对照组给予甲氨蝶呤治疗,托法替布组在对照组治疗的基础上给予托法替布治疗,2组均治疗观察12周,比较2组患者的滑膜增生程度与骨侵蚀变化情况、肌骨超声半定量评分、生活质量评分及治疗期间不良反应发生率.结果:2组治疗12周后的骨侵蚀评分、滑膜增生评分均低于治疗前,且托法替布组治疗12周后骨侵蚀评分、滑膜增生评分均低于对照组,差异均有统计学意义(P<0.05).2组治疗期间恶心呕吐、嗜睡、静脉血栓、白细胞减少等不良反应发生率对比,差异无统计学意义(P>0.05).2组治疗12周后的肌骨超声半定量评分均低于治疗前,且托法替布组治疗12周后的肌骨超声半定量评分低于对照组,差异均有统计学意义(P<0.05).托法替布组治疗12周后的功能状况、情感状况、社会功能状况、生理功能状况等生活质量评分均高于对照组,组间差异有统计学意义(P<0.05).结论:托法替布在类风湿关节炎患者的应用能缓解滑膜增生程度与骨侵蚀程度,且不会增加不良反应的发生,还可降低患者的肌骨超声半定量评分,提高患者的生活质量,从而持续改善患者的预后.

Objective:To explore and analyze the intervention effect of tofacatib on patients with rheumatoid arthritis.Methods:80 patients with rheumatoid arthritis in our hospital from June 2021 to January 2023 were selected as research objects,and were divided into a Tofacitib group and a control group according to random number table method,with 40 cases each.The control group was treated with methotrexate,and the tofacatib group was treated with tofacatib on the basis of the control group.Both groups were observed for 12 weeks,and the degree of synovial hyperplasia and changes in bone erosion,musculoskeletal ultrasound semi-quantitative score,quality of life score and incidence of adverse reactions during treatment were compared between the two groups.Results:The bone erosion score and synovial hyperplasia score of the 2 groups after 12 weeks of treatment were lower than before treatment,and the bone erosion score and synovial hyperplasia score of the Tofacatib group after 12 weeks of treatment were lower than the control group,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions such as nausea,vomiting,lethargy,venous thrombosis and leukopenia between 2 groups during treatment(P>0.05).The musculoskeletal ultrasound semi-quantitative score after 12 weeks of treatment in both groups was lower than before treatment,and the musculoskeletal ultrasound semi-quantitative score after 12 weeks of treatment in Tofacitib group was also lower than that in control group,with statistical significance(P<0.05).After 12 weeks of treatment,life quality scores such as functional status,emotional status,social function and physiological function in Tofacatib group were higher than those in control group,and the differences were statistically significant(P<0.05).Conclusion:The application of tofacatib in patients with rheumatoid arthritis can alleviate the degree of synovial hyperplasia and bone erosion without increasing the occurrence of adverse reactions,and can also reduce the semi-quantitative musculoskeletal ultrasound score of patients,improve the quality of life of patients,and thus continue to improve the prognosis of patients.